DFCO Stock Overview
Dalrada Financial Corporation, together with its subsidiaries, operates as a technology and manufacturing company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Dalrada Financial Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$0.46 |
| 52 Week Low | US$0.062 |
| Beta | 1.36 |
| 1 Month Change | 25.33% |
| 3 Month Change | -3.59% |
| 1 Year Change | 121.44% |
| 3 Year Change | -62.39% |
| 5 Year Change | 375.95% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DFCO | US Industrials | US Market | |
|---|---|---|---|
| 7D | -18.3% | 0.7% | 1.0% |
| 1Y | 121.4% | -11.7% | 21.9% |
Return vs Industry: DFCO exceeded the US Industrials industry which returned -11.7% over the past year.
Return vs Market: DFCO exceeded the US Market which returned 21.9% over the past year.
Price Volatility
| DFCO volatility | |
|---|---|
| DFCO Average Weekly Movement | 15.9% |
| Industrials Industry Average Movement | 4.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DFCO has not had significant price volatility in the past 3 months.
Volatility Over Time: DFCO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | n/a | Brian Bonar | www.dalrada.com |
Dalrada Financial Corporation, together with its subsidiaries, operates as a technology and manufacturing company. It operates through Genefic, Dalrada Energy Services, Dalrada Precision Manufacturing, and Dalrada Technologies divisions. The Genefic division processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus; markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based products; and provides prescription management, education, nursing, and total health solutions; distributes alcohol-free hand sanitizers, surface cleaners, laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, and kits, as well as dispensers, stands, and ease of use packaging for the end consumers.
Dalrada Financial Corporation Fundamentals Summary
| DFCO fundamental statistics | |
|---|---|
| Market cap | US$18.18m |
| Earnings (TTM) | -US$22.48m |
| Revenue (TTM) | US$31.32m |
0.6x
P/S Ratio-0.8x
P/E RatioIs DFCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DFCO income statement (TTM) | |
|---|---|
| Revenue | US$31.32m |
| Cost of Revenue | US$23.49m |
| Gross Profit | US$7.83m |
| Other Expenses | US$30.32m |
| Earnings | -US$22.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 25.01% |
| Net Profit Margin | -71.78% |
| Debt/Equity Ratio | -262.3% |
How did DFCO perform over the long term?
See historical performance and comparison